scholarly journals Hyperthyroidism and vascular cell adhesion molecule-1 are associated with a low ankle-brachial index

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Yu-Hsuan Li ◽  
I-Te Lee
Keyword(s):  
Cell Adhesion Molecule ◽  
Regression Coefficient ◽  
Ankle Brachial Index ◽  
Antithyroid Drugs ◽  
Graves Disease ◽  
Vascular Cell Adhesion ◽  
Free T4 ◽  
Vascular Cell ◽  
Cell Adhesion Molecule 1

Abstract We aimed to assess the ankle-brachial index (ABI) in patients with Graves’ disease. In the cross-sectional assessments, 81 patients with drug-naïve Graves’ disease and 235 with euthyroidism were enrolled. ABI and vascular cell adhesion molecule-1 (VCAM-1) levels were assessed. In the prospective follow-up, 32 patients with Graves’ disease were assessed again after antithyroid drugs for at least 4 weeks, and 32 age- and sex-matched controls with euthyroidism were also followed up. Patients with Graves’ disease had a higher VCAM-1 level (1309 ± 292 vs. 1009 ± 168 ng/mL, P < 0.001) and a lower ABI (0.98 ± 0.11 vs. 1.06 ± 0.10, P < 0.001) than those with euthyroidism. ABI was significantly lower in patients with hyperthyroidism and a high VCAM-1 level than in those with euthyroidism and a low VCAM-1 level (regression coefficient: − 0.050, 95% confidence interval [CI] between − 0.080 and − 0.019; P = 0.001). After treatment with antithyroid drugs, the change in free thyroxine (T4) level was inversely associated with the percentage change in ABI (regression coefficient: − 0.003, 95% CI between − 0.005 and − 0.001, P = 0.001). A synergistic effect of VCAM-1 and free T4 on ABI reduction was observed. After a longitudinal follow-up, an increase in ABI was significantly correlated with a decrease in the free T4 level.

Clinical significance of serum vascular cell adhesion molecule-1(VCAM-1) in colorectal cancer.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 550-550
Author(s):  
Rumeysa Ciftci ◽  
Nuri Faruk Aykan ◽  
Ece Aksit ◽  
Ceren Tilgen Yasasever ◽  
Sezai Vatansever ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cell Adhesion ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Vascular Cell Adhesion ◽  
Vascular Cell ◽  
Vascular Cell Adhesion Molecule ◽  
Clinicopathologic Parameters ◽  
Cell Adhesion Molecule 1

550 Background: Vascular cell adhesion molecule-1 (VCAM-1) is a transmembrane glycoprotein, which is expressed on endothelium and contributes in leukocyte adhesion and extravasation during inflammation. It has been demonstrated that VCAM-1 is over-expressed on colorectal cancer (CRC) cells and plays role in metastasis development and angiogenesis. We aimed to compare serum VCAM-1 levels of CRC patients with heathy controls and evaluate its relationship with clinicopathologic parameters, treatment response and overall survival (OS). Methods: The study enrolled 111 patients with histopathologically confirmed CRC followed up between February 2010-September 2013 in Institute of Oncology, Istanbul University and 30 sex- and age-matched healthy controls. Pre-treatment serum VCAM-1 levels were determined by the solid-phase sandwich ELISA method. Results: The cancer localisation was rectum in 40% and colon in 60% of patients. Metastatic disease was present in 51.4%. Forty percent of 40 metastatic patients who received palliative chemotherapy (CT) was CT-responsive (partial or complete response). The median serum VCAM-1 level was significantly higher in CRC patients than controls (p<0.001). In addition, serum VCAM-1 level was significantly higher in diabetic CRC patients than those without diabetes (p=0.03). There was no significant relationship between other clinicopathologic parameters, stage, carcinoembrionic antigen (CEA), CA19.9 and VCAM-1. The median follow-up period was 12 (±8.2) months. Progression was observed in 16.2 % of patients and 18 % of patients had died at the time of analysis. The presence of metastasis (p<0.001) and elevated CEA level (p<0.001) were factors affecting OS significantly. Serum VCAM-1 did not have a significant impact on OS in both univariate (p=0.55) and multivariate analysis (p=0.23). Conclusions: Serum VCAM-1 level is significantly higher in patients with CRC than controls. However, it has no prognostic or predictive role for CT response. Studies randomising CRC patients in more homogenous treatment arms to evaluate the effect of systemic treatment on serum VCAM-1 with longer follow-up period are needed.

scholarly journals Two Novel PET Radiopharmaceuticals for Endothelial Vascular Cell Adhesion Molecule-1 (VCAM-1) Targeting

Pharmaceutics ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1025
Author(s):  
Sara Pastorino ◽  
Sara Baldassari ◽  
Giorgia Ailuno ◽  
Guendalina Zuccari ◽  
Giuliana Drava ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Umbilical Vein ◽  
In Vitro Tests ◽  
Vascular Cell Adhesion ◽  
Vascular Cell ◽  
Vascular Cell Adhesion Molecule ◽  
Cell Adhesion Molecule 1 ◽  
Pet Radiopharmaceuticals

Atherosclerosis is a chronic progressive disease involving inflammatory events, such as the overexpression of adhesion molecules including the endothelial Vascular Cell Adhesion Molecule-1 (VCAM-1). VCAM-1 is rapidly overexpressed in the first stages of atherosclerosis, thus representing a promising target for early atheroma detection. Two novel Positron Emission Tomography (PET) radiopharmaceuticals (MacroP and NAMP), based on the VCAM-1-binding peptide having sequence VHPKQHRGGSKGC, were synthesized and characterized. MacroP is derived from the direct conjugation of a DOTA derivative with the peptide, while NAMP is a biotin derivative conceived to be employed in a three-step pretargeting system, involving the use of a double-chelating derivative of DOTA. The identity of the newly synthesized radiopharmaceuticals was confirmed by mass spectrometry and, after radiolabeling with 68Ga, both showed high radiochemical purity; in vitro tests on human umbilical vein endothelial cells evidenced their VCAM-1 binding ability, with higher radioactive uptake in the case of NAMP. Moreover, NAMP might also be employed in a theranostic approach in association with functionalized biotinylated nanoparticles.

Sign in / Sign up

Export Citation Format

Share Document